

**Viltepso (vitolarсен)  
Effective 05/01/2021**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Duchenne’s Muscular Dystrophy is a form of rapidly worsening muscular dystrophy. DMD is caused by a defective gene for dystrophin.

Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

**Coverage Guidelines**

Authorization may be reviewed for members new to the plan who are currently receiving treatment with Viltepso excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**

Authorization may be granted when documentation is provided for patients who meet the following criteria:

1. The member has a diagnosis of Duchenne Muscular Dystrophy
2. The member has genetic testing was confirming the diagnosis of DMD and to identify the specific type of DMD gene mutation.
3. The DMD gene mutation is amenable to exon 53 skipping (refer to examples in Appendix).
4. The member will be initiating treatment with Viltepso prior to age of 10
5. The member is able to walk independently without assistive devices.
6. The member dose will not exceed 80 mg/kg.
7. The requested medication will be not used Vyondys 53 (golodirsен)

**Continuation of Therapy**

Reauthorization may be granted when ALL of the following criteria are met:



1. The member has demonstrated a response to therapy as evidenced by remaining ambulatory (e.g., not wheelchair dependent).
2. The member will not exceed a dose of 80 mg/kg.
3. The requested medication will be not used concomitantly with Vyondys 53 (golodirsen)

### **Limitations**

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months.

### **Appendix**

Examples of DMD gene mutations (exon deletions) amenable to exon 53 skipping

1. Deletion of exon 52
2. Deletion of exon 45-52
3. Deletion of exon 47-52
4. Deletion of exon 48-52
5. Deletion of exon 49-52
6. Deletion of exon 50-52

### **References**

1. Viltepso [package insert]. Paramus, NJ: NS Pharma, Inc.; August 2020.
2. Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy. *Mol Ther Nucleic Acids*. 2018;13:442–449. doi:10.1016/j.omtn.2018.09.017

### **Review History**

3/17/2021 – Created and Reviewed at March P&T. Effective 05/01/2021

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.